Current Urology Reports

, 19:61 | Cite as

Erectile Dysfunction and Lower Urinary Tract Symptoms

  • Cosimo De NunzioEmail author
  • Riccardo Lombardo
  • Giorgia Tema
  • Andrea Tubaro
Benign Prostatic Hyperplasia (K McVary, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Benign Prostatic Hyperplasia


Purpose of Review

In the past years, the relationship between lower urinary tract symptoms and erectile dysfunction has been widely explored. The aim of our systematic review is to summarize the published evidence over the past year on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED).

Recent Findings

Recent data support the relationship between LUTS and ED in Eastern Europe and in Asia. The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence.


LUTS and ED are prevalent conditions in men over 50; epidemiologically, the relationship between both conditions has been confirmed all over the world. PDE5i alone or in combination with alpha blockers can be considered the gold standard for the treatment of young patients with storage symptoms and concomitant ED. In clinical research, a better understanding of the molecular pathways behind this association may also help to identify new possible targets and develop novel therapeutic approaches to manage both disorders; the identification of new biomarkers of both disorders is also compulsory in this area.


Prostate LUTS Erectile dysfunction Diagnosis Outcome Treatment 


Compliance with Ethical Standards

Conflict of Interest

Cosimo De Nunzio, Riccardo Lombardo, Giorgia Tema, and Andrea Tubaro each declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12:305–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Gacci M, Andersson K-E, Chapple C, Maggi M, Mirone V, Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017;6:295–304.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kardasevic A, Milicevic S. Correlation of subjective symptoms in patients with benign prostatic hyperplasia and erectile dysfunction. Med Arch. 2017;71:32–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Plata M, Caicedo JI, Trujillo CG, Mariño-Alvarez ÁM, Fernandez N, Gutierrez A, et al. Prevalence of metabolic syndrome and its association with lower urinary tract symptoms and sexual function. Actas Urol Esp. 2017;41:522–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Adegun PT, Areo PO, Solomon A, Dada SA, Adebayo PB. Erectile dysfunction in men with and without lower urinary tract symptoms in Nigeria. World J Mens Health. 2017;35:107–14.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tibaek S, Gard G, Dehlendorff C, et al. Lower urinary tract symptoms, erectile dysfunction, and quality of life in poststroke men. Am J Mens Health. 2017;
  10. 10.
    Calogero AE, Burgio G, Condorelli RA, et al. Lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction: from physiology to clinical aspects. Aging Male. 2018:1–10.Google Scholar
  11. 11.
    De Nunzio C, Roehrborn CG, Andersson K-E, et al. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus. 2017;3:352–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J Androl. 2004;25:470–8.CrossRefPubMedGoogle Scholar
  13. 13.
    De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Higashi Y. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3′,5′-monophosphate pathway. Int J Urol. 2017;24:412–24.CrossRefPubMedGoogle Scholar
  15. 15.
    De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13:613–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Rosen RC. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int. 2006;97:29–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, et al. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology. 2004;63:1148–52.CrossRefPubMedGoogle Scholar
  18. 18.
    WANG Y, BAO Y, LIU J, DUAN L, CUI Y. Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis. LUTS Low Urin Tract Symptoms. 2018;10:84–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Ng KK, Ng FC. The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men. Asian J Urol. 2017;4:191–4.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    •• Oelke M, Wagg A, Takita Y, Büttner H, Viktrup L. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled cli. BJU Int. 2017;119:793–803. Pooled analysis on efficacy of tadalafil of randomised clinical trials summarizes efficacy of tadalafil 5 mg. CrossRefPubMedGoogle Scholar
  21. 21.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, et al. Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med. 2017;14:1018–27.CrossRefPubMedGoogle Scholar
  22. 22.
    Yoshida T, Kinoshita H, Shimada S, Taguchi M, Matsuda T. Comparison of silodosin monotherapy vs silodosin with tadalafil add-on therapy in patients with benign prostatic hyperplasia. Urology. 2017;106:153–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Matsukawa Y, Majima T, Matsuo K, Funahashi Y, Kato M, Yamamoto T, et al. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study. Int J Urol. 2018;25:246–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male. 2018;21:77–82.CrossRefPubMedGoogle Scholar
  25. 25.
    Francomano D, Ilacqua A, Cortese A, Tartaglia G, Lenzi A, Inghilleri M, et al. Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. J Endocrinol Investig. 2017;40:275–9.CrossRefGoogle Scholar
  26. 26.
    Ko WJ, Han HH, Ham WS, Lee HW. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5:671–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Sokhal AK, Sankhwar S, Goel A, Singh K, Kumar M, Purkait B, et al. A prospective study to evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active men treated for benign prostatic hyperplasia by alpha blockers. Urology. 2017;
  29. 29.
    Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30
  30. 30.
    • Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121:647–58. Important level 1 evidence on side effects of combination therapy. CrossRefPubMedGoogle Scholar
  31. 31.
    Haider KS, Haider A, Doros G, Traish A. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257–65.CrossRefPubMedGoogle Scholar
  32. 32.
    Quarto G, Cola A, Perdonà S. Efficacy of a formulation containing Serenoa repens, Crocus sativus and Pinus massoniana extracts in men with concomitant LUTS and erectile dysfunction. Minerva Urol Nefrol. 2017;69:300–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Cosimo De Nunzio
    • 1
    Email author
  • Riccardo Lombardo
    • 1
  • Giorgia Tema
    • 1
  • Andrea Tubaro
    • 1
  1. 1.Department of Urology, Sant’Andrea Hospital“La Sapienza” UniversityRomeItaly

Personalised recommendations